ENDPOINTS

Oric locks down cash for Phase 3 prostate cancer trial with early data in hand

Oric Pharmaceuticals has secured funds to support a planned Phase 3 study of its prostate cancer drug scheduled for 2026 after early results showed “broad and deep” clinical responses. The California biotech

May 29, 2025 - 12:24
 0
Oric locks down cash for Phase 3 prostate cancer trial with early data in hand
Oric Pharmaceuticals has secured funds to support a planned Phase 3 study of its prostate cancer drug scheduled for 2026 after early results showed “broad and deep” clinical responses. The California biotech
Read More

Tags:

Previous Article

FDA rejects Stealth's rare disease drug, but offers potential for accelerated ap...

Next Article

In the workplace, relationships equal reality

Related Posts

Investors pump $130M into protein degrader startup GlycoEra

Investors pump $130M into protein degrader startup Glyc...

May 27, 2025  0

Some generics, biosimilar drugmakers say they can withstand tariff impact

Some generics, biosimilar drugmakers say they can withs...

May 13, 2025  0

FDA adcomm narrowly votes against UroGen’s bladder cancer drug

FDA adcomm narrowly votes against UroGen’s bladder canc...

May 21, 2025  0